

Indices	Value	Pts	Chg (%)
SENSEX	48878.54	(746.22)	-1.50%
NIFTY	14371.90	(218.45)	-1.50%
SGX NIFTY*	15177.00	(20.00)	-0.13%
DOW Jones	31430.70	(7.10)	-0.02%
S&P	3916.38	6.50	0.17%
Nasdaq	14025.77	53.24	0.38%
FTSE	6528.72	4.36	0.07%
CAC	5669.82	(0.98)	-0.02%
DAX	14040.91	107.94	0.77%
Shanghai Composite*	NA	NA	NA
Nikkei*	29494.72	(68.21)	-0.23%
Hang Seng*	NA	NA	NA

\*As at 8.00 am

Most Active Call & Put			
Symbol	Strike Price	OI (000)	Chg (%)
NIFTY	15200CE	68991	54%
NIFTY	15100PE	35152	0%

Commodity	Price	Pts	Chg (%)
NYMEX Crude (USD)	57.86	-0.38	(0.66)
Brent Crude (USD)	60.80	-0.34	(0.56)
Gold (USD)	1825.20	-1.60	(0.09)

Currency	Value	Pts	Chg (%)
USD/Rupee	72.72	3.30	0.05
Euro/Rupee	88.25	0.02	0.00
Pound/Rupee	100.39	-0.02	0.00

Indicators	Value	Pts	Chg (%)
India VIX	23.04	-0.91	-3.8

Indicators	Value	Bps
India 10-Yr Yield	5.962%	-0.042
US 10-Yr Yield	1.162%	0.003

Trade Statistics	BSE	NSE	F & O
Turnover (INR Crs)	4631	66798	6881039
Advance (Nos)	1682	28	NA
Declines (Nos)	1314	22	NA
Unchanged	130	0	NA

## Market Summary

The Indian markets snapped their two-day losing run in the previous session, although Friday may again see the benchmark indices open on a flat-to-negative note amid muted global cues. Investors will today track key macroeconomic data -- the industrial production data for December and CPI inflation data for January. Besides, corporate results and stock-specific developments will also sway the markets.

A total of 953 companies, including Grasim Industries, Bharat Forge, Glenmark Pharmaceuticals, Apollo Hospitals, and Mazagon Dock Shipbuilders, are set to announce their quarterly earnings today.

On Wall Street, prices held near records as investors bet on more government spending, although enthusiasm was tempered when US President Joe Biden argued for more infrastructure spending by saying in part that China was poised to "eat our lunch." Overall, the Nasdaq and S&P 500 eked out gains of 0.4 per cent and 0.2 per cent, respectively, while the Dow Jones slipped 0.02 per cent.

In Friday's early Asian trade, the Australian ASX 200 index and Japan's Nikkei were down 0.3 per cent, each. Markets in Greater China and most of Southeast Asia are closed on Friday for the Lunar New Year holiday.

## Macro News

### Education, healthcare, agriculture got bulk of \$2.6 billion impact investments in 2020

The year 2020 was not just the year of pandemic but also the year of realisation. Environment, agriculture and health came to the fore like never before. There is an increased interest in regenerative companies that take care of people, products and planets alike.

Despite the global pandemic and its impact on business and economy, there was a rise in investment in impact enterprises that are solving critical social and environmental problems, as per India Impact Investors Council's annual report for 2020 -- "Retrospect: India Impact Investment Trends". According to the report, impact enterprises received around \$2.6 billion in investment across 243 equity deals.

The report found that at an absolute level, impact investing volumes fell 25% in calendar year (CY) 2020 as compared with CY2019. However, investors are willing to bet on early-stage enterprises, especially in agriculture, livelihood and healthcare sector. There was a 16% rise in seed stage investment volume reflecting the interest in the sector despite the pandemic.

The year 2020 was a big-bang year for education sector, attracting investments totaling about \$660 million across 47 deals, with online test prep and K10 segments leading the way.

Ramraj Pai, Chief Executive Officer, India Impact Investors Council (IIC) said, "The Indian impact investing sector is clearly coming of age. Notwithstanding the pandemic, Indian impact enterprises have proved to be resilient: we see continued interest from investors in investing in a variety of innovative tech led impact ideas."

Institutional Activity	Cash	
	11-Feb-21	10-Feb-21
<b>FII (INR Crs)</b>		
Buy	5628	9072
Sell	4683	7285
Net	944	1787
<b>DII (INR Crs)</b>		
Buy	4271	4750
Sell	4979	6826
Net	-708	-2076

FII Derivative Statistics			
Particulars	Buy (INR Crs)	Sell (INR Crs)	OI (Nos)
INDEX FUTURES	4280	4139	115529
INDEX OPTIONS	578374	575813	1027588
STOCK FUTURES	15096	15338	1202690
STOCK OPTIONS	14205	14496	178582
Total	611955	609786	

Gainers & Losers	Price	Chg (%)
<b>Gainers (INR)</b>		
Hindalco	295.4	5.7
Reliance	2055.7	4.12
Sun Pharma	643.65	2.64
Adani Ports	591.85	2.6
GAIL	136.45	2.13
<b>Losers (INR)</b>		

Eicher Motors	2818.15	-2.87
NTPC	97.3	-2.55
Titan Company	1524.7	-2.46
Larsen	1530.5	-1.44
Tata Motors	325	-1.19

Sectoral Performance	Value	Pts	Chg (%)
S&P BSE Small Cap	19626.01	205.94	1.06
S&P BSE Mid-Cap	19898.48	88.35	0.45
S&P BSE Auto	24747.56	-102.45	-0.41
S&P BSE BANKEX	40435.30	-25.53	-0.06
S&P BSE Capital Goods	21857.57	-214.18	-0.97
S&P BSE FMCG	12708.09	99.05	0.79
S&P BSE Healthcare	21903.45	47.38	0.22
S&P BSE IT	25863.50	-1.26	0.00
S&P BSE Metals	12785.90	130.27	1.03
S&P Oil & Gas	15012.65	224.09	1.52

## Key News

### ITC Q3 result

The company has reported revenue of Rs.11787 crores during the period ended December 31, 2020 as compared to Rs.11806 crores during the period ended December 31, 2019. OPM during the same period fell 300 bps to 36%. The company has posted net profit of Rs.3663 crores for the period ended December 31, 2020 as against net profit of Rs.4142 crores for the period ended December 31, 2019.

Revenue from cigarette segment rose 3.5 per cent to Rs 5,498 crore, while that from FMCG - Others segment, which excludes cigarette business, rose 7.5 per cent to Rs 3,562 crore.

The EBITDA of FMCG - Others segment rose 28 per cent to Rs 326 crore, while its margin expanded 150 basis points to 9.2 per cent on higher operating leverage, enhanced operational efficiencies, portfolio premiumisation and product mix enrichment.

"The significant surge in demand for staples and convenience foods witnessed during the lockdown phase ebbed during the quarter with consumers broadening their purchase assortment and lower 'at-home' consumption on the back of increased mobility," ITC said.

While revenue from hotels segment, hit severely by the coronavirus pandemic, declined 57.4 per cent to Rs 235 crore, paperboard, paper and packaging segment saw a 5 per cent fall in revenue at Rs 1,478 crore. However, agri business revenue jumped 18.5 per cent to Rs 2,482 crore, driven by higher wheat supplies for Aashirvaad atta and trading opportunities in rice, soya and wheat exports.

On a consolidated basis, ITC's net profit declined 11.3 per cent to Rs 3,527 crore. The company's board also declared an interim dividend of Rs 5 per share.

### Ashok Leyland Q3 result

On a consolidated basis, the company has reported revenue of Rs.5954 crores during the period ended December 31, 2020 as compared to Rs.5189 crores during the period ended December 31, 2019. OPM during the same period fell 100 bps to 13%. The company has posted net profit of Rs.14 crores for the period ended December 31, 2020 as against net profit of Rs.27 crores for the period ended December 31, 2019.

### MRF Q3 result

On a consolidated basis, the company has reported revenue of Rs.4642 crores during the period ended December 31, 2020 as compared to Rs.4076 crores during the period ended December 31, 2019. OPM during the same period rose 600 bps to 21%. The company has posted net profit of Rs.521 crores for the period ended December 31, 2020 as against net profit of Rs.241 crores for the period ended December 31, 2019.

### UFLEX Q3 result

On a consolidated basis, the company has reported revenue of Rs.2105 crores during the period ended December 31, 2020 as compared to Rs.1793 crores during the period ended December 31, 2019. OPM during the same period rose 500 bps to 20%. The company has posted net profit of Rs.160 crores for the period ended December 31, 2020 as against net profit of Rs.85 crores for the period ended December 31, 2019.

February 12,  
2021



Equity Research Desk

**Analyst Certification of Independence:** The analyst(s) for this report certifies that all the views expressed in this report accurately reflect his or her personal views about the subject company(ies) or issuers and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of SPA Securities Limited, and have no bearing whatsoever on any recommendation that they have given in the Research Report. Disclaimer and Disclosures as required under SEBI (Research Analyst) Regulations, 2014: SPA Securities Limited (hereinafter refer as SPA Securities) and its affiliates are engaged in investment banking, investment advisory, stock broking, institutional equities, Mutual Fund Distributor and insurance broking. SPA Securities is a SEBI registered securities broking Company having membership of NSE, BSE & MSEI for Equity, Future & Option, Currency Derivatives segment and Wholesale Debt Market. The Company is focused primarily on providing securities broking services to institutional clients and is empanelled as an approved securities broker with all the major Nationalised, Private and Co-operative banks, Corporate houses, Insurance Companies, Financial Institutions, Asset Management Companies and Provident Fund Trusts. Details of affiliates are available on our website i.e. [www.spasecurities.com](http://www.spasecurities.com).

SPA Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. Vide SEBI Reg. No. INH00002615.

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in the last five years. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities, nor has our certificate of registration been cancelled by SEBI at any point of time.

**General Disclosures:** This Research Report (hereinafter called "report") has been prepared by SPA Securities and is meant for sole use by the recipient and not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, (as defined under section 2(h) of securities Contracts (Regulation) Act.1956, through SPA Securities nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments.

This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by SPA Securities to be reliable, although its accuracy and completeness cannot be guaranteed. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. Any review, retransmission or any other use is prohibited.

The information, opinions, views expressed in this Research Report are those of the research analyst as at the date of this Research Report which are subject to change and do not represent to be an authority on the subject. While we would endeavour to update the information herein on a reasonable basis, we are under no obligation to update the information. Also, there may be regulatory, compliance or other reasons that prevent us from doing so. Hence all such information and opinions are subject to change without notice.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein.

This Research Report should be read and relied upon at the sole discretion and risk of the recipient. If you are dissatisfied with the contents of this complimentary Research Report or with the terms of this Disclaimer, your sole and exclusive remedy is to stop using this Research Report. Neither SPA Securities nor its affiliates or their respective directors, employees, agents or representatives shall be responsible or liable in any manner, directly or indirectly, for the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.a

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. SPA Securities may have issued other reports in the past that are inconsistent with and reach different conclusion from the information presented in this report.

SPA Securities, its affiliates and employees may, from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com) and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>. (Choose a company from the list on the browser and select the "three years" icon in the price chart).

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SPA Securities or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SPA Securities.

List of Associates as per SEBI (Research Analyst) Regulations, 2014

Statements on ownership and material conflicts of interest, compensation - SPA and Associates

Disclosure of interest statement	Yes/No
SPA Securities/its Affiliates/Analyst/his or her Relative financial interest in the company	No
SPA Securities/its Affiliates/Analyst/his or her Relative actual/beneficial ownership of more than 1% in subject company at the end of the month. Immediately preceding the date of the publication of the research report or date of public appearance.	No
Investment banking relationship with the company covered	No
Any other material conflict of interest at the time of publishing the research report	No
Receipt of compensation by SPA Securities or its Affiliated Companies from the subject company covered for in the last twelve months:	
<ul style="list-style-type: none"> <li>Managing/co-managing public offering of securities</li> <li>Investment banking/merchant banking/brokerage services</li> <li>products or services other than those above</li> <li>in connection with research report</li> </ul>	No
Whether Research Analyst has served as an officer, director or employee of the subject company covered	No
Whether the Research Analyst or Research Entity has been engaged in market making activity of the Subject Company;	No

For statements on ownership and material conflicts of interest, compensation, etc. for individual Research Analyst(s), please refer to each specific research report.

SPA Securities Ltd: Mittal Court, A-Wing, 10th Floor, Nariman Point, Mumbai - 400 021, Tel. No. : +91-022-4289 5600, Fax: +91 (22) 2657 3708/9

**SPA GLOBAL PRIVATE LIMITED**  
Mutual Fund Advisor  
AMFI Reg. No. 90796

SPA SECURITIES LTD	SEBI REG. NOS.
NSE Cash	INZ000241036
NSE Future & Option	INZ000241036
NSE Currency Derivatives	INZ000241036
BSE Cash	INZ000241036
BSE Currency Derivatives	INZ000241036
MSEI Cash	INZ000241036
MSEI Future & Option	INZ000241036
MSEI Currency Derivatives	INZ000241036
Mutual Fund	ARN 77388
CDSL DP	IN-DP-CDSL-485-2008
NSDL DP	IN-DP-NSDL-316-2009
SEBI Research Analyst	INH100002615
Merchant Banker	INM000012740